Bär & Karrer Advises the Sellers of Humabs BioMed
The owners of Humabs BioMed SA, a Swiss biotechnology firm located in Bellinzona and focused on discovering and developing fully human monoclonal antibodies to treat serious infections with a unique proprietary discovery technology, sold their interests to Vir Biotechnology Inc. Vir Biotechnology is founded by ARCH Venture Partners and seeded by ARCH, the Bill & Melinda Gates Foundation, Altitude Life Science Ventures, Alta Partners and further investors. They aim at creating a global platform to transform the care of people with serious infectious diseases.
Bär & Karrer acted as legal advisor of the sellers in this transaction. The team included Paolo Bottini, Edoardo Buzzi and Paolo Ader (all M&A) and Markus Wang (IP).